A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin

Detalhes bibliográficos
Autor(a) principal: Nunes,Ana Luísa
Data de Publicação: 2021
Outros Autores: Santos,Daniela, Figueiredo,Carolina, Ferreira,Diana M., Lima,Jandira, Santos,Arsénio
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2021000400030
Resumo: Abstract Drug induced liver injury (DILI) is a condition with a wide clinical spectrum. The diagnosis represents a challenge not only due to the large number of known hepatotoxic products but especially when the substance involved is not known to induce liver damage. Empagliflozin is linked to several adverse effects but has not been convincingly associated to DILI. We report a case of a 70-year-old type 2 diabetic woman that presented with gastrointestinal symptoms 1 month after empagliflozin introduction. Elevated hepatic enzymes were found and despite ultrasound evidence of vesicular microlithiasis, no biliary obstruction was confirmed. Other causes of liver injury were excluded and the diagnosis of DILI secondary to empagliflozin was made after liver biopsy. Complete clinical and laboratorial resolution was verified after empagliflozin withdrawal. Only two cases of DILI were reported since empagliflozin licensure which makes this case more interesting, alerting clinicians to an early diagnosis and appropriate treatment.
id RCAP_63d908db48b06507cf58c26317ae24a3
oai_identifier_str oai:scielo:S0872-671X2021000400030
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling A Rare Case of Drug Induced Liver Injury Secondary to EmpagliflozinChemical and Drug Induced Liver InjurySodium-Glucose Transporter 2 Inhibitors/adverse effects.Abstract Drug induced liver injury (DILI) is a condition with a wide clinical spectrum. The diagnosis represents a challenge not only due to the large number of known hepatotoxic products but especially when the substance involved is not known to induce liver damage. Empagliflozin is linked to several adverse effects but has not been convincingly associated to DILI. We report a case of a 70-year-old type 2 diabetic woman that presented with gastrointestinal symptoms 1 month after empagliflozin introduction. Elevated hepatic enzymes were found and despite ultrasound evidence of vesicular microlithiasis, no biliary obstruction was confirmed. Other causes of liver injury were excluded and the diagnosis of DILI secondary to empagliflozin was made after liver biopsy. Complete clinical and laboratorial resolution was verified after empagliflozin withdrawal. Only two cases of DILI were reported since empagliflozin licensure which makes this case more interesting, alerting clinicians to an early diagnosis and appropriate treatment.Sociedade Portuguesa de Medicina Interna2021-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/reporttext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2021000400030Medicina Interna v.28 n.4 2021reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2021000400030Nunes,Ana LuísaSantos,DanielaFigueiredo,CarolinaFerreira,Diana M.Lima,JandiraSantos,Arsénioinfo:eu-repo/semantics/openAccess2024-02-06T17:08:35Zoai:scielo:S0872-671X2021000400030Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:20:55.369380Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
title A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
spellingShingle A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
Nunes,Ana Luísa
Chemical and Drug Induced Liver Injury
Sodium-Glucose Transporter 2 Inhibitors/adverse effects.
title_short A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
title_full A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
title_fullStr A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
title_full_unstemmed A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
title_sort A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
author Nunes,Ana Luísa
author_facet Nunes,Ana Luísa
Santos,Daniela
Figueiredo,Carolina
Ferreira,Diana M.
Lima,Jandira
Santos,Arsénio
author_role author
author2 Santos,Daniela
Figueiredo,Carolina
Ferreira,Diana M.
Lima,Jandira
Santos,Arsénio
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Nunes,Ana Luísa
Santos,Daniela
Figueiredo,Carolina
Ferreira,Diana M.
Lima,Jandira
Santos,Arsénio
dc.subject.por.fl_str_mv Chemical and Drug Induced Liver Injury
Sodium-Glucose Transporter 2 Inhibitors/adverse effects.
topic Chemical and Drug Induced Liver Injury
Sodium-Glucose Transporter 2 Inhibitors/adverse effects.
description Abstract Drug induced liver injury (DILI) is a condition with a wide clinical spectrum. The diagnosis represents a challenge not only due to the large number of known hepatotoxic products but especially when the substance involved is not known to induce liver damage. Empagliflozin is linked to several adverse effects but has not been convincingly associated to DILI. We report a case of a 70-year-old type 2 diabetic woman that presented with gastrointestinal symptoms 1 month after empagliflozin introduction. Elevated hepatic enzymes were found and despite ultrasound evidence of vesicular microlithiasis, no biliary obstruction was confirmed. Other causes of liver injury were excluded and the diagnosis of DILI secondary to empagliflozin was made after liver biopsy. Complete clinical and laboratorial resolution was verified after empagliflozin withdrawal. Only two cases of DILI were reported since empagliflozin licensure which makes this case more interesting, alerting clinicians to an early diagnosis and appropriate treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2021000400030
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2021000400030
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-671X2021000400030
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
dc.source.none.fl_str_mv Medicina Interna v.28 n.4 2021
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137296083058688

Registros relacionados